Sebastian F. Michels
Kerpener Str. 62
Koeln, NW 50937, Germany
Koeln, NW 50937, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 12, 2026
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Response to Trastuzumab Deruxtecan in a Patient With EGFR-Mutated NSCLC and Transformation to SCLC Harboring HER2 Amplification: A Case Report.
Journal: JTO clinical and research reports
Published: October 29, 2025
An agentic framework for autonomous scientific discovery in cancer pathology.
Journal: Nature medicine
Published: September 02, 2025
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.
Journal: JTO clinical and research reports
Published: July 30, 2025
Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 20, 2025
Development and clinical validation of a prognostic algorithm for stroma-tumor ratio quantification in non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 31, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 12, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.
Journal: Clinical lung cancer
Published: March 26, 2024
Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms.
Journal: Cell reports. Medicine
Published: March 13, 2024
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 06, 2023
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Journal: ESMO open
Published: August 15, 2023
Last Updated: 09/26/2026